Embedded Files
DelveInsight’s “Cushing’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report delivers a thorough comprehension of Cushing’s Disease, encompassing historical and projected epidemiology alongside Cushing’s Disease market trends across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The most recent healthcare forecast report presents an extensive examination of Cushing’s Disease, supplying detailed perspectives on Cushing’s Disease revenue patterns, incidence, and therapeutic environment. The report explores essential Cushing’s Disease data, emphasizing the present and anticipated market scale, while assessing the effectiveness and progress of novel Cushing’s Disease treatments. Furthermore, it addresses the realm of Cushing’s Disease clinical trials, offering a summary of active and forthcoming research that could influence the future of Cushing’s Disease management. This document serves as a vital tool for grasping market forces and the advancing treatment choices in the Cushing’s Disease domain.
To gain deeper knowledge about the Cushing’s Disease market outlook, drug adoption, treatment scenarios, and epidemiology trends, click here: Cushing’s Disease Market Forecast.
Key highlights from the Cushing’s Disease Market Report include:
The Cushing’s Disease market size was estimated at approximately USD 1,089 million in 2025 and is expected to expand at a substantial CAGR of 5.90% over the study period (2020-2034).
Leading Cushing’s Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Recordati, Xeris Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others.
Prominent Cushing’s Disease Therapies: Relacorilant (CORT125134), Clofutriben (SPI-62), ISTURISA (osilodrostat), RECORLEV (levoketoconazole), SIGNIFOR (pasireotide), KORLYM* (mifepristone), Lu AG13909*, ST-002***, Atumelnant (CRN04894), and others.
The Cushing’s Disease market is poised for growth due to the condition's rising incidence and heightened awareness in the coming years. Moreover, the introduction of multiple pipeline products at various development stages will notably transform the Cushing’s Disease market landscape.
In 2024, the United States reported an estimated 19,950 diagnosed prevalent cases of Cushing’s disease, with figures anticipated to increase from 2025 to 2034.
In 2024, diagnosed prevalent cases of Cushing’s disease in the US totaled about 4,450 for males and 15,500 for females.
In 2024, the EU4 and the UK documented approximately 12,400 diagnosed prevalent cases of Cushing’s disease, including roughly 2,650 in males and 9,750 in females.
In 2024, age-specific data in the US indicated that adults represented the bulk of diagnosed Cushing’s disease cases, with nearly 17,950 instances, while children had about 2,000 cases. These figures are projected to grow from 2025 to 2034.
Endogenous Cushing’s syndrome is divided into ACTH-dependent and ACTH-independent categories. ACTH-dependent cases constitute 80–85% of all occurrences, with 75–80% stemming from ACTH release by a pituitary adenoma, referred to as Cushing’s disease.
In 2024, the 7MM recorded roughly 37,100 diagnosed prevalent cases of Cushing’s disease, with the United States holding the predominant portion.
In 2024, across the 7MM, females exhibited a greater number of diagnosed prevalent cases of Cushing’s disease than males.
Identifying Cushing’s disease poses significant challenges due to its uncommon nature, symptom similarities with other illnesses, and diverse clinical manifestations. Merely 40–60% of patients display a visible tumor on routine MRI, and the typical diagnosis delay spans about seven years.
The anticipated five-year survival rate for those with untreated Cushing’s disease is around 50%.
SIGNIFOR and SIGNIFOR LAR remain the sole treatments explicitly approved for Cushing’s disease, whereas ISTURISA is prescribed for Cushing’s disease in the US and for endogenous Cushing’s syndrome in the EU and Japan.
"The Cushing’s disease pipeline features numerous promising treatments in mid- and late-stage development. Standout contenders include Relacorilant (CORT125134) by Corcept Therapeutics, Clofutriben (SPI-62) by Sparrow Pharmaceuticals, and Atumelnant (CRN04894) by Crinetics Pharmaceuticals.
Cushing’s Disease Overview
Cushing’s Disease is an uncommon endocrine condition resulting from excessive cortisol hormone production, typically triggered by a pituitary gland tumor secreting surplus adrenocorticotropic hormone (ACTH). This surplus ACTH prompts the adrenal glands, causing heightened cortisol levels in the body.
Obtain a Free sample of the Cushing’s Disease Market Forecast, Size & Share Analysis Report:
Cushing’s Disease Epidemiology
The epidemiology segment offers perspectives on historical, present, and future epidemiology patterns in the seven major markets (7MM) spanning 2020 to 2034. It aids in identifying the roots of existing and anticipated trends through various studies and expert opinions. The epidemiology section also delivers an in-depth review of the diagnosed patient base and upcoming patterns.
Cushing’s Disease Epidemiology Segmentation:
The Cushing’s Disease market report provides epidemiological analysis for the period 2020–2034 in the 7MM, divided into:
Total Prevalence of Cushing’s Disease
Prevalent Cases of Cushing’s Disease by Severity
Gender-Specific Prevalence of Cushing’s Disease
Diagnosed Cases of Episodic and Chronic Cushing’s Disease
Download the report to learn which factors are influencing Cushing’s Disease epidemiology trends @ Cushing’s Disease Epidemiology Forecast
Cushing’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section concentrates on the adoption rate of potential medications recently introduced or slated for launch in the Cushing’s Disease market during the study timeframe. The analysis encompasses Cushing’s Disease market uptake by drugs, patient adoption by therapies, and revenue from each medication.
Additionally, the therapeutics evaluation section clarifies medications with the swiftest uptake and the underlying reasons for their widespread application. It also compares drugs based on market share.
The report further covers Cushing’s Disease Pipeline Development Activities. It furnishes insightful details on diverse therapeutic candidates at different phases and the primary firms engaged in creating targeted treatments. It also examines recent advancements, such as partnerships, takeovers, mergers, licensing, patent information, and other details for upcoming therapies.
Cushing’s Disease Therapies and Key Companies
Relacorilant (CORT125134): Corcept Therapeutics
Clofutriben (SPI-62): Sparrow Pharmaceuticals
ISTURISA (osilodrostat): Recordati
RECORLEV (levoketoconazole): Xeris Pharmaceuticals
SIGNIFOR (pasireotide): Recordati
KORLYM* (mifepristone): Corcept Therapeutics
Lu AG13909*: H. Lundbeck
ST-002***: Stero Therapeutics
Atumelnant (CRN04894): Crinetics Pharmaceuticals
Explore more about therapies expected to capture significant Cushing’s Disease market share @ Cushing’s Disease Treatment Landscape
Cushing’s Disease Market Drivers
Growing incidence and diagnosed cases of Cushing’s disease worldwide, enlarging the patient base.
Enhanced awareness among healthcare providers and patients, facilitating prompt diagnosis and intervention.
Progress in diagnostic methods, including advanced imaging and biochemical assays, improving disease identification.
Continuous innovation in novel treatments, such as selective glucocorticoid receptor blockers and precision medications.
Favorable regulatory framework, including orphan drug status, encouraging pharmaceutical advancements.
Cushing’s Disease Market Barriers
Diagnostic challenges due to symptom similarities with other conditions and the disease's rarity, leading to treatment delays.
Restricted approved treatments, limiting options for patients.
Elevated treatment expenses, particularly for sophisticated or prolonged therapies.
Limited patient numbers, potentially reducing appeal for new drug development.
Possible adverse effects and long-term issues from existing treatments, affecting patient compliance and results.
Scope of the Cushing’s Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cushing’s Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Recordati, Xeris Pharmaceuticals, Corcept Therapeutics, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others
Key Cushing’s Disease Therapies: Relacorilant (CORT125134), Clofutriben (SPI-62), ISTURISA (osilodrostat), RECORLEV (levoketoconazole), SIGNIFOR (pasireotide), KORLYM* (mifepristone), Lu AG13909*, ST-002***, Atumelnant (CRN04894), and others
Cushing’s Disease Therapeutic Assessment: Cushing’s Disease current marketed and Cushing’s Disease emerging therapies
Cushing’s Disease Market Dynamics: Cushing’s Disease market drivers and Cushing’s Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cushing’s Disease Unmet Needs, KOL’s views, Analyst’s views, Cushing’s Disease Market Access and Reimbursement
To learn more about Cushing’s Disease companies active in the treatment sector, visit @ Cushing’s Disease Clinical Trials and Therapeutic Assessment
Table of Contents
Cushing’s Disease Market Report Introduction
Executive Summary for Cushing’s Disease
SWOT analysis of Cushing’s Disease
Cushing’s Disease Patient Share (%) Overview at a Glance
Cushing’s Disease Market Overview at a Glance
Cushing’s Disease Disease Background and Overview
Cushing’s Disease Epidemiology and Patient Population
Country-Specific Patient Population of Cushing’s Disease
Cushing’s Disease Current Treatment and Medical Practices
Cushing’s Disease Unmet Needs
Cushing’s Disease Emerging Therapies
Cushing’s Disease Market Outlook
Country-Wise Cushing’s Disease Market Analysis (2020–2034)
Cushing’s Disease Market Access and Reimbursement of Therapies
Cushing’s Disease Market Drivers
Cushing’s Disease Market Barriers
Cushing’s Disease Appendix
Cushing’s Disease Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
About DelveInsight
DelveInsight is a premier Healthcare Business Consultant and Market Research firm specializing in life sciences. It assists Pharma companies with holistic end-to-end solutions to enhance performance.
It also provides Healthcare Consulting Services, aiding in market analysis to boost business growth and tackle challenges effectively.
Contact Us
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse